Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Handrean Soran

Showing results (11-20 of 196) with videos related to

Pageof 20
Sort By:
Diabetes, Obesity & Metabolism|June 18, 2009
Aspirin therapy and primary prevention of cardiovascular disease in diabetes mellitusNaveed Younis, Steve Williams, Handrean Soran
BMJ (Clinical Research Ed.)|July 18, 2020
Obesity and covid-19: the unseen risksAkheel A Syed, Handrean Soran, Safwaan Adam
BMJ (Clinical Research Ed.)|August 23, 2008
Hypercholesterolaemia and its managementDeepak Bhatnagar, Handrean Soran, Paul N Durrington
Current Opinion in Lipidology|September 9, 2022
What should be the goal of cholesterol-lowering treatment? A quantitative evaluation dispelling guideline mythsPaul N Durrington, Bilal Bashir, Handrean Soran
Atherosclerosis|December 12, 2018
Reply to: "Comments on 'Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk' "Handrean Soran, Safwaan Adam, Paul N Durrington
European Journal of Preventive Cardiology|September 10, 2016
Are recent statin recommendations to employ fixed doses and abandon targets effective for treatment of hypercholesterolaemia? Investigation based on number needed to treatHandrean Soran, Safwaan Adam, Paul N Durrington
Vascular Health and Risk Management|July 11, 2009
The role of insulin detemir in overweight type 2 diabetes managementYared N Demssie, Naveed Younis, Handrean Soran
British Journal of Hospital Medicine (London, England : 2005)|April 10, 2009
Tight glycaemic control and cardiovascular disease in type 2 diabetesYared N Demssie, Handrean Soran, Naveed Younis
Frontiers in Cardiovascular Medicine|March 6, 2023
Paraoxonase 1 and atherosclerosisPaul N Durrington, Bilal Bashir, Handrean Soran
Atherosclerosis|October 2, 2018
Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease riskHandrean Soran, Safwaan Adam, Paul N Durrington
Pageof 20

Showing results (11-20 of 196) with videos related to

Sort By:
Pageof 20
Diabetes, Obesity & Metabolism|June 18, 2009
Aspirin therapy and primary prevention of cardiovascular disease in diabetes mellitusNaveed Younis, Steve Williams, Handrean Soran
BMJ (Clinical Research Ed.)|July 18, 2020
Obesity and covid-19: the unseen risksAkheel A Syed, Handrean Soran, Safwaan Adam
BMJ (Clinical Research Ed.)|August 23, 2008
Hypercholesterolaemia and its managementDeepak Bhatnagar, Handrean Soran, Paul N Durrington
Current Opinion in Lipidology|September 9, 2022
What should be the goal of cholesterol-lowering treatment? A quantitative evaluation dispelling guideline mythsPaul N Durrington, Bilal Bashir, Handrean Soran
Atherosclerosis|December 12, 2018
Reply to: "Comments on 'Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk' "Handrean Soran, Safwaan Adam, Paul N Durrington
European Journal of Preventive Cardiology|September 10, 2016
Are recent statin recommendations to employ fixed doses and abandon targets effective for treatment of hypercholesterolaemia? Investigation based on number needed to treatHandrean Soran, Safwaan Adam, Paul N Durrington
Vascular Health and Risk Management|July 11, 2009
The role of insulin detemir in overweight type 2 diabetes managementYared N Demssie, Naveed Younis, Handrean Soran
British Journal of Hospital Medicine (London, England : 2005)|April 10, 2009
Tight glycaemic control and cardiovascular disease in type 2 diabetesYared N Demssie, Handrean Soran, Naveed Younis
Frontiers in Cardiovascular Medicine|March 6, 2023
Paraoxonase 1 and atherosclerosisPaul N Durrington, Bilal Bashir, Handrean Soran
Atherosclerosis|October 2, 2018
Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease riskHandrean Soran, Safwaan Adam, Paul N Durrington
Pageof 20